There are 2949 resources available
1425MO - Effects of elemental diet for gastrointestinal adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil (EPOC 2 study: JFMC49-1601-C5): A phase III randomized controlled trial
Presenter: Hiroya Takeuchi
Session: Mini Oral - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
612MO - Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: Results from PROREPAIR-A study
Presenter: Rebeca Lozano Mejorada
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
614MO - Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects
Presenter: Mihaela Aldea
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA22 - Imaging based PCa screening among BRCA mutation carriers: Results from the first round of screening
Presenter: David Margel
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
615MO - Phase Ib/II study of VERU-111, novel, oral tubulin inhibitor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen blocking agent
Presenter: Mark Markowski
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
616MO - Efficacy of BN-brachyury (BNVax) + bintrafusp alfa (BA) + N-803 in castration-resistant prostate cancer (CRPC): Results from a preliminary analysis of the Quick Efficacy Seeking Trial (QuEST1)
Presenter: Jason Redman
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
617MO - Repurposing metformin as an anticancer drug: Preliminary results of randomized controlled trial in advanced prostate cancer (MANSMED)
Presenter: Reham Alghandour
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
618MO - Local therapy to the primary tumour for newly diagnosed, oligo-metastatic prostate cancer: A prospective randomized, phase II, open-label trial
Presenter: Bo Dai
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
1585MO - Factors associated with change in overall survival and quality of life between time of approval and post-marketing among anti-cancer therapies
Presenter: Aida Bujosa Rodríguez
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1586MO - Pivotal trial endpoints of drugs for rare and non-rare cancers in the US and Europe
Presenter: Kerstin Vokinger
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast